Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS ) 35.08 -0.51 (-1.43%) Streaming Delayed Price Updated: 10:57 AM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about GeneDx Holdings Corp. - Class A Common Stock < Previous 1 2 Next > GeneDx to Participate in Fall Investor Conferences August 12, 2024 From GeneDx Via Business Wire GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From GeneDx Via Business Wire GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients July 30, 2024 From GeneDx Via Business Wire GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights July 30, 2024 From GeneDx Via Business Wire GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024 July 11, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients June 10, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients June 05, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx to Participate in Upcoming Investor Conferences May 22, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Reports First Quarter 2024 Financial Results and Business Highlights April 29, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset April 23, 2024 The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine From GeneDx Holdings Corp. Via GlobeNewswire GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 April 04, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics March 14, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx to Participate in 44th Annual Cowen Health Care Conference February 26, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024 February 20, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 February 01, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 24, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Announces Preliminary 2023 Financial Results January 08, 2024 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy December 01, 2023 New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene... From GeneDx Holdings Corp. Via GlobeNewswire GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 20, 2023 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights October 30, 2023 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023 October 09, 2023 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 22, 2023 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Announces Evolution of Executive Leadership Team September 11, 2023 Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs amplifying the GeneDx brand and leadership... From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced September 06, 2023 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine August 21, 2023 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 08, 2023 From GeneDx Holdings Corp. Via GlobeNewswire GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights August 08, 2023 From GeneDx Holdings Corp. Via GlobeNewswire PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care August 07, 2023 Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms From GeneDx Holdings Corp.; PacBio Via GlobeNewswire GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options July 19, 2023 Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients From GeneDx Holdings Corp. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.